Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 21;79(1):150.
doi: 10.1186/s13690-021-00663-8.

Optimal strategies for COVID-19 prevention from global evidence achieved through social distancing, stay at home, travel restriction and lockdown: a systematic review

Tadele Girum  1 , Kifle Lentiro  1 , Mulugeta Geremew  2 , Biru Migora  2 , Sisay Shewamare  3 , Mulugeta Shegaze Shimbre  4
Affiliations
Review

Optimal strategies for COVID-19 prevention from global evidence achieved through social distancing, stay at home, travel restriction and lockdown: a systematic review

Tadele Girum et al. Arch Public Health. .

Abstract

Background: Coronavirus disease (COVID-19) is a global public health agenda with high level of pandemicity. There is no effective treatment, but prevention strategies can alter the pandemic. However, the effectiveness of existing preventive measures and strategies is inconclusive. Therefore, this study aimed to review evidence related to COVID-19 prevention achieved through social distancing, stay at home, travel ban and lockdown in order to determine best practices.

Methods/design: This review has been conducted in accordance with the PRISMA and Cochrane guideline. A systematic literature search of articles archived from major medical databases (MEDLINE, SCOPUS, CINAHL, PsycINFO, and Web of Science) and Google scholar was done. Observational and modeling researches published to date with information on COVID-19 prevention like social distancing, stay at home, travel ban and lockdown were included. The articles were screened by two experts. Risk of bias of included studies was assessed through ROBINS-I tool and the certainty of evidence was graded using the GRADE approach for the main outcomes. The findings were presented by narration and in tabular form.

Results: A total of 25 studies was included in the review. The studies consistently reported the benefit of social distancing, stay at home, travel restriction and lockdown measures. Mandatory social distancing reduced the daily growth rate by 9.1%, contacts by 7-9 folds, median number of infections by 92% and epidemic resolved in day 90. Travel restriction and lockdown averted 70.5% of exported cases in china and doubling time was increased from 2 to 4 days. It reduced contacts by 80% and decreased the initial R0, and the number of infected individuals decreased by 91.14%. Stay at home was associated with a 48.6 and 59.8% reduction in weekly morbidity and fatality. Obligatory, long term and early initiated programs were more effective.

Conclusion: Social distancing, stay at home, travel restriction and lockdown are effective to COVID-19 prevention. The strategies need to be obligatory, initiated early, implemented in large scale, and for a longer period of time. Combinations of the programs are more effective. However, the income of individuals should be guaranteed and supported.

Keywords: COVID-19; Social distancing; Stay at home; Travel restriction and lockdown.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest with anybody.

Figures

Fig. 1
Fig. 1
Flow chart for study search, selection and screening for the review
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization (WHO). Naming the coronavirus disease (COVID-19) and the virus that causes it”. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technica...
    1. World Health Organization (WHO). Rolling updates on coronavirus diseases (COVID-19). Available from www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-theyha...
    1. Guan W, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei CL, Hui DSC, du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. World Health Organization. Novel coronavirus (2019-nCOV). Situation Report 51. 2020 [Available from: https://www.who.int/docs/default-source/ coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62 e57_10.
    1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A trial of lopinavir– ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382(19):1787–1799. doi: 10.1056/NEJMoa2001282. - DOI - PMC - PubMed

LinkOut - more resources